Leslie J Dorfman, MD
Neurology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 18
- 4 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
18 plans · 4 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Dorfman’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
18 of 18 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence G18144 · Current
Licensed to practise in California · since 1970 · expires 2027-09-30 · Albert Einstein College of Medicine of Yeshiva University.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$2,236
Medicare paid this office $2,236 for 19 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
Who their Medicare patients are
19 Original Medicare patients in 2024. Average age 67 · Health risk score 1.42. At or below the middle of the specialty; the typical neurology clinician is at 1.61.
The office billed $16,862, Medicare allowed $3,120 and paid $2,236; for 27 services of 7 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 19 | 27 | 67 | 1.42 | $16,862 | $2,236 |
| 2023 | 21 | 35 | 65 | 1.88 | $11,638 | $2,266 |
| 2022 | 21 | 32 | 64 | 2.07 | $16,073 | $2,338 |
| 2021 | 21 | 30 | 61 | 1.26 | $21,030 | $2,290 |
| 2020 | 39 | 69 | 66 | 1.64 | $82,163 | $4,406 |
| 2019 | 71 | 148 | 68 | 1.49 | $215,140 | $10,176 |
| 2018 | 65 | 127 | 65 | 1.76 | $203,910 | $8,946 |
| 2017 | 67 | 125 | 64 | 1.46 | $154,827 | $8,386 |
| 2016 | 60 | 118 | 62 | 1.43 | $135,522 | $7,708 |
| 2015 | 66 | 127 | 63 | 1.54 | $159,170 | $8,377 |
| 2014 | 91 | 189 | 64 | 1.13 | $160,916 | $12,369 |
| 2013 | 122 | 296 | 67 | 1.37 | $159,250 | $14,855 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 1 service
| Return visit (30+ min) | 13 | $1,445 | $63 |
2022: 1 service
| Return visit (30+ min) | 12 | $1,557 | $71 |
2021: 1 service
| Return visit (30+ min) | 16 | $1,268 | $67 |
2020: 1 service
| Return visit (30+ min) | 21 | $1,930 | $67 |
2019: 4 services
| Long return visit (40+ min) | 26 | $2,854 | $92 |
| Muscle electrical test | 26 | $1,651 | $40 |
| Return visit (30+ min) | 13 | $789 | $61 |
| Muscle electrical test | 11 | $283 | $17 |
2018: 2 services
| Long return visit (40+ min) | 21 | $2,467 | $88 |
| Muscle electrical test | 19 | $1,028 | $41 |
2017: 2 services
| Long return visit (40+ min) | 26 | $2,989 | $88 |
| Muscle electrical test | 18 | $1,025 | $41 |
2016: 3 services
| Long return visit (40+ min) | 16 | $1,942 | $84 |
| Muscle electrical test | 15 | $1,044 | $42 |
| Return visit (30+ min) | 11 | $897 | $60 |
2015: 4 services
| Long return visit (40+ min) | 25 | $2,567 | $89 |
| New patient visit (45+ min) | 13 | $1,269 | $98 |
| Muscle electrical test | 16 | $801 | $42 |
| Muscle electrical test | 13 | $414 | $17 |
2014: 6 services
| Muscle electrical test | 39 | $1,761 | $42 |
| Long return visit (40+ min) | 12 | $1,381 | $99 |
| Nerve test | 15 | $1,353 | $90 |
| Return visit (30+ min) | 17 | $1,189 | $59 |
| Nerve test | 12 | $870 | $73 |
| Muscle electrical test | 28 | $670 | $17 |
2013: 8 services
| Nerve test | 33 | $3,100 | $94 |
| Muscle electrical test | 55 | $2,055 | $33 |
| New patient visit (60+ min) | 11 | $1,365 | $124 |
| Long return visit (40+ min) | 12 | $1,343 | $90 |
| Nerve test | 19 | $1,336 | $70 |
| Muscle electrical test | 44 | $1,307 | $17 |
| Return visit (30+ min) | 15 | $1,156 | $64 |
| Nerve test | 18 | $1,039 | $58 |
Drugs they prescribed that Part D paid
$2,405
Pharmacies billed $2,405 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 78) in 2024. At or below the middle of the specialty; the typical neurology clinician is at 0%.
74 generic and fewer than 11 brand-name prescriptions · $2,405 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Teriflunomide | 11 | $1,101 | $100 |
| Modafinil | 13 | $106 | $8 |
Year by year
| 2024 | 78 | 13 | 0% (0) | None | $2,405 |
| 2023 | 125 | 19 | None | 14% | $159,630 |
| 2022 | 142 | 16 | None | 25% | $330,895 |
| 2021 | 160 | 20 | None | 28% | $405,856 |
| 2020 | 201 | 24 | None | 33% | $665,252 |
| 2019 | 224 | 24 | 0% (0) | 36% | $663,888 |
| 2018 | 204 | 22 | 0% (0) | 55% | $700,449 |
| 2017 | 167 | 19 | 0% (0) | 57% | $583,669 |
| 2016 | 106 | 18 | None | 74% | $370,297 |
| 2015 | 127 | 19 | None | 63% | $360,994 |
| 2014 | 86 | 16 | 0% (0) | 64% | $238,749 |
| 2013 | 94 | 17 | None | 55% | $147,455 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 3 drugs
| Gabapentin | 15 | $189 | $13 |
| Zolpidem | 14 | $20 | $1 |
| Alprazolam | 12 | $10 | $1 |
2022: 7 drugs
| Avonex | 13 | $103,927 | $7,994 |
| Tecfidera | 11 | $99,926 | $9,084 |
| Vumerity | 11 | $91,198 | $8,291 |
| Glatopa | 12 | $32,256 | $2,688 |
| Modafinil | 11 | $179 | $16 |
| Alprazolam | 14 | $82 | $6 |
| Zolpidem | 18 | $48 | $3 |
2021: 8 drugs
| Avonex | 13 | $100,229 | $7,710 |
| Vumerity | 11 | $88,382 | $8,035 |
| Glatopa | 12 | $32,256 | $2,688 |
| Carbamazepine Er | 11 | $562 | $51 |
| Baclofen | 11 | $507 | $46 |
| Modafinil | 11 | $319 | $29 |
| Alprazolam | 13 | $84 | $6 |
| Zolpidem | 13 | $73 | $6 |
2020: 5 drugs
| Aubagio | 30 | $295,389 | $9,846 |
| Tecfidera | 12 | $107,555 | $8,963 |
| Avonex | 13 | $98,264 | $7,559 |
| Amantadine | 11 | $1,050 | $95 |
| Modafinil | 12 | $202 | $17 |
2019: 7 drugs
| Tecfidera | 30 | $239,464 | $7,982 |
| Aubagio | 31 | $233,808 | $7,542 |
| Avonex | 14 | $103,602 | $7,400 |
| Glatiramer Acetate | 21 | $68,697 | $3,271 |
| Dalfampridine Er | 18 | $7,983 | $443 |
| Baclofen | 11 | $1,055 | $96 |
| Gabapentin | 13 | $293 | $23 |
2018: 6 drugs
| Tecfidera | 32 | $242,137 | $7,567 |
| Aubagio | 33 | $235,649 | $7,141 |
| Copaxone | 11 | $66,420 | $6,038 |
| Ampyra | 13 | $33,612 | $2,586 |
| Baclofen | 12 | $1,208 | $101 |
| Sertraline | 21 | $87 | $4 |
2017: 6 drugs
| Tecfidera | 34 | $276,163 | $8,122 |
| Copaxone | 23 | $134,069 | $5,829 |
| Aubagio | 14 | $89,532 | $6,395 |
| Amantadine | 15 | $2,563 | $171 |
| Sertraline | 18 | $105 | $6 |
| Zolpidem | 12 | $46 | $4 |
2016: 3 drugs
| Copaxone | 24 | $128,957 | $5,373 |
| Tecfidera | 19 | $120,654 | $6,350 |
| Aubagio | 17 | $98,357 | $5,786 |
2015: 5 drugs
| Copaxone | 24 | $119,346 | $4,973 |
| Tecfidera | 18 | $100,072 | $5,560 |
| Aubagio | 18 | $92,127 | $5,118 |
| Oxybutynin Chloride | 16 | $773 | $48 |
| Hydrocortisone | 12 | $87 | $7 |
2014: 2 drugs
| Copaxone | 23 | $109,159 | $4,746 |
| Tecfidera | 12 | $62,787 | $5,232 |
2013: 2 drugs
| Aubagio | 17 | $66,610 | $3,918 |
| Ampyra | 16 | $23,834 | $1,490 |
Money from drug and device companies
$150 in 2025
| 2025 | 1 | 1 | $150 | $150 |
| 2019 | 1 | 1 | None | $56 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Biogen | Tysabri | $150 | 1 payment
|
See the published payment
| Biogen | Consulting · 2025-05-22 | Tysabri | $150 |
See earlier years (2019)
2019: $56
| Biogen | None | $56 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1255382065
- Licence
- CA G18144California G18144: Current · expires 2027-09-30
- Trained
- Albert Einstein College of Medicine of Yeshiva University, 1968
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Neurology (2084N0400X); Federal specialty code 204R00000X (204R00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2006-05-15
- NPI last updated
- 2023-11-07
- NPI record certified
- 2023-11-07
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 725 Welch Rd, Palo Alto, CA, 94304